Mandate

Vinge advises Vostok New Ventures Ltd in connection with an investment in the ride-sharing service BlaBlaCar

August 11, 2016

Vinge has advised Vostok New Ventures Ltd (”Vostok”) in connection with an investment in the Paris based ride-sharing service Comuto SA (”BlaBlaCar”). Through the investment, Vostok has acquired shares in BlaBlaCar for a value of approximately EUR 40 million. The acquisition was made by an issue in kind where the purchase price for the shares in BlaBlaCar consisted of 6,866,766 newly issued shares in Vostok. The acquisition was approved by the Special General Meeting in Vostok on 5 August 2016 and new Swedish depository receipts for the issued shares are expected to be admitted for trading on Nasdaq Stockholm on 11 August 2016. Following the acquisition, Vostok owns approximately 5.4 % of the shares in BlaBlaCar.

Vostok New Ventures Ltd is an investment company with a special focus on online marketplaces and businesses with strong network effects. As of 31 March 2016, the net asset value of the group was USD 507.59 million. The Swedish depository receipts of Vostok New Ventures are listed on Nasdaq Stockholm, Mid Cap segment.

Vinge’s team primarily consisted of Jesper Schönbeck, Johan Göthberg, David Andersson, Amanda Knutsson, Nils Fredrik Dehlin and Ludvig Berke.

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025